Sustained Virologic Response

Researchers discovered potential for a simplified monitoring schedule compared with standard monitoring among certain patients treated direct-acting antivirals for chronic hepatitis C, according to data published in Journal of Hepatology.

Patients who developed hepatitis C-related hepatocellular carcinoma after achieving sustained virologic response with interferon-free direct-acting antivirals had a 60% to 70% improvement in 5-year survival compared with untreated patients.

Results from a real-world study of implementing hepatitis C testing into integrated care centers that deliver HIV services to people who inject drugs demonstrated superior infection awareness, testing and treatment compared with usual care.

With several highly effective, curative direct-acting antiviral options for patients with hepatitis C, the focus has changed from management of the viral infection to a march toward global elimination.

The FDA has expanded the approval of Mavyret for a treatment duration of 8 weeks to include treatment-naive adults and children aged 12 years and older with chronic hepatitis C genotype 1 through 6 and compensated cirrhosis.